Lupin gets US FDA nod to market postherpetic neuralgia drug

Lupin has announced that it has received approval from the US health regulator to market its generic Gabapentin tablets used for treatment of postherpetic neuralgia in the American market.

The company has received final approval to market its Gabapentin tablets USP in the strengths of 600 mg and 800 mg from the US FDA, Lupin said in a statement.

As per the IQVIA MAT June 2018 data, Gabapentin tablets USP, 600 mg and 800 mg had annual sales of around USD 180.7 million in the US, Lupin said.

The product is indicated for the treatment of postherpetic neuralgia in adults and adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalisation, in adults and pediatric patients 3 years and older with epilepsy.

 --------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.